The court has reached a verdict in a patent infringement suit brought against a worldwide developer, manufacturer and marketer of medical devices, the Boston Scientific Corporation (NYSE: BSX).
The suit was filed by Dr. Bruce Saffran, who claimed that the company's TAXUS(R) Express(R) and TAXUS(R) Liberte(TM) drug-eluting stent products violated Dr. Saffran's patent while the latter being valid.
The jury awarded Dr. Saffran damages of $431 million.
The company manufactures products used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Boston Scientific is well known for the development of the Taxus Stent, a drug-coated stent which is used to open clogged arteries.
Boston Scientific plans to overturn the verdict on the basis of suppositions that the verdict is unsupported by both the evidence and the law.
In a weary world of endless US military interventions, sanctions, trade tariffs and chaos, let’s pause and take stock of the shining house on the hill